Vendor Intelligence Report: Shandong Aishi Biotechnology

Executive summary

Across 74 Finnrick lab tests, Shandong Aishi Biotechnology records 61 pass and 13 fail — an overall pass rate of 82%. The result is not evenly distributed across the catalog: GHK-Cu is the clearest positive signal, Tesamorelin is the weak internal choice, and Tirzepatide plus Retatrutide sit in a middle zone where current-batch verification matters more than the vendor average.

The main laboratory risk is dosing reliability, not basic identity. The report documents high-purity signals alongside fill-accuracy failures, including a retained Retatrutide outlier severe enough to change how the aggregate score should be read. Ratings also fall under stricter methodology, which matters for buyers who care about dose precision rather than only research-peptide purity thresholds.

The corporate story is sharper than the product page suggests. Registry records show a 2025 Dezhou company controlled by one person, with zero insured employees, while TikTok marketing presents ISO22716/GMPC, clean-workshop and production-line claims. The investigation found no public peptide/pharma GMP authorization, leaving Shandong Aishi better understood as a young export-facing entity unless facility-level proof is produced.

Operationally, the vendor has enough infrastructure to sell, but not enough to make authentication easy: intermittent DNS, a commodity B2B website template, free-email contact, mixed mainland and Hong Kong sales channels, no Wayback footprint, and unresolved Qichacha penalty flags. The full report turns those fragments into a product-by-product buyer read rather than a blanket verdict.

Inside the full report:

• Per-product pass/fail rates, rating trajectories and methodology-divergence charts for the tested catalog
• Qichacha corporate registry analysis covering ownership, formation, address, employee signal and penalty flags
• Claim-versus-record review of TikTok ISO22716/GMPC, clean-workshop and production-line marketing
• RDAP, DNS, certificate-transparency, Wayback and GuideChem/21Food infrastructure findings
• Contact-channel mapping across Gmail, QQ, mainland phone, Hong Kong sales numbers, TikTok and Instagram
• Reputation, affiliate-promotion and supply-chain visibility checks, including forum, X/web, ImportYeti and SAMR coverage gaps

Risk assessment

• Product-specific dosing reliability risk — high: Tesamorelin is fail-heavy (6 tests, 3 pass / 3 fail, 47.27%); Retatrutide has a documented severe underfill outlier despite a current 82.21%; Tirzepatide remains mixed at 79.2%.
• Batch traceability risk — medium: Tested vials were described as no-label/silver-crimp with inconsistent or missing batch IDs, limiting COA matching and recall accountability across products.
• Unverified manufacturing-claim risk — high: TikTok claims ISO22716/GMPC, 100,000-level workshops and 18 production lines, but no public peptide/pharma GMP authorization was found and Qichacha lists zero insured employees.
• Corporate transparency and enforcement uncertainty risk — medium: One-person LLC formed April 30, 2025; Zhang Yiguo holds all roles; Qichacha lists two penalties whose details were not found in the national SAMR database.
• Operational and channel reliability risk — medium: Intermittent DNS failures, no Wayback snapshots, commodity GuideChem/21Food site, free Gmail and mixed +852/+86 sales channels weaken buyer authentication.